NCT00520169View on ClinicalTrials.gov

Absolute Bioavailability and Nasopharyngeal Absorption of Intranasal Ketamine

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Healthy
Interventions
DRUG

intranasal ketamine

A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.

Trial Locations (1)

02140

Javelin Pharmaceuticals, Cambridge

Sponsors
All Listed Sponsors
lead

Javelin Pharmaceuticals

INDUSTRY